Our top pick for
CohBar Inc is a biotechnology business based in the US. CohBar shares (CWBR) are listed on the NASDAQ and all prices are listed in US Dollars. CohBar employs 11 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$0.96|
|52-week range||$0.88 - $2.20|
|50-day moving average||$1.13|
|200-day moving average||$1.25|
|Wall St. target price||$6.60|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.30|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||0.9605|
|1 month (2021-09-16)||-14.24%|
|3 months (2021-07-16)||-8.52%|
|6 months (2021-04-16)||-15.00%|
|1 year (2020-10-16)||-1.89%|
|2 years (2019-10-16)||-26.68%|
|3 years (2018-10-16)||4.25|
|5 years (2016-10-14)||2.15|
|Gross profit TTM||$0|
|Return on assets TTM||-69.99%|
|Return on equity TTM||-173.04%|
|Market capitalisation||$61.9 million|
TTM: trailing 12 months
There are currently 2.2 million CohBar shares held short by investors – that's known as CohBar's "short interest". This figure is 4.3% up from 2.1 million last month.
There are a few different ways that this level of interest in shorting CohBar shares can be evaluated.
CohBar's "short interest ratio" (SIR) is the quantity of CohBar shares currently shorted divided by the average quantity of CohBar shares traded daily (recently around 1.3 million). CohBar's SIR currently stands at 1.76. In other words for every 100,000 CohBar shares traded daily on the market, roughly 1760 shares are currently held short.
However CohBar's short interest can also be evaluated against the total number of CohBar shares, or, against the total number of tradable CohBar shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CohBar's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 CohBar shares in existence, roughly 30 shares are currently held short) or 0.0439% of the tradable shares (for every 100,000 tradable CohBar shares, roughly 44 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against CohBar.
Find out more about how you can short CohBar stock.
We're not expecting CohBar to pay a dividend over the next 12 months.
Over the last 12 months, CohBar's shares have ranged in value from as little as $0.875 up to $2.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CohBar's is 2.827. This would suggest that CohBar's shares are significantly more volatile than the average for this exchange and represent a higher risk.
CohBar, Inc. , a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, acute respiratory distress syndrome, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases, CB5064 analogs for COVID-19 associated ARDS, MBT5 analogs for CXCR4-related cancer and orphan diseases, and MBT3 analogs for cancer immunotherapy. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.